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Abstract
Apelin and chemerin are adipocytokines that play important roles in many physiological and pathological processes through-
out the body. Our previous study demonstrated that these two adipokines are expressed and secreted by epithelial and 
granulosa cancer cell lines. 17β-estradiol (E2) and insulin-like growth factor-1 (IGF-1) are important regulators of ovarian 
functions, and their roles are well known. This study investigated whether apelin and chemerin regulate proliferation and 
apoptosis of epithelial (OVCAR-3) and granulosa (COV434) ovarian cancer cell lines by interacting with E2 and IGF-1. 
Apelin and chemerin did not affect caspase-3 activation in either cell line. However, apelin abrogated the stimulatory effects 
of E2 on proliferation of OVCAR-3 cells and of IGF-1 on proliferation of COV434 cells independently of ERK1/2 and PI3K 
via crosstalk of apelin receptor with estrogen receptor alpha and IGF-1 receptor, respectively.
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Abbreviations
APLNR  Apelin receptor
E2  17β-estradiol
ERα  Estrogen receptor alpha
ERβ  Estrogen receptor beta
GPR30  G protein-coupled receptor 30
G15  GPR30 antagonist
IGF-1  Insulin-like growth factor-1
IGF1R  Insulin-like growth factor-1 receptor
LY294002  Selective inhibitor of phosphatidylinositol 3 
kinase selective inhibitor of phosphatidy
ML221  Apelin receptor antagonist
MPP  Estrogen receptor alpha antagonist
P/A ratio  Proliferation/apoptosis ratio
PD98059  Selective inhibitor of mitogen-activated pro-
tein kinase kinases
PHTPP  Estrogen receptor beta antagonist
Introduction
Adipose tissue is one of the largest endocrine organs in 
the body and has endocrinologic, metabolic, and immu-
noregulatory roles. The multifunctionality of adipose tissue 
is dependent on its ability to synthesize and release sev-
eral bioactive compounds including hormones, cytokines, 
extracellular matrix proteins, and growth factors, which 
influence a variety of physiological and pathophysiological 
processes. Several reports indicate that ovarian cells express 
adipose tissue hormones, called adipokines, and their recep-
tors [1–6]. Moreover, our previous studies demonstrated 
that ovarian cancer cells express adipokine receptors and 
also synthesize and secrete adipokines such as apelin [7] 
and chemerin [8]. These findings suggest that apelin and 
chemerin have paracrine and autocrine actions in ovarian 
cancer cells.
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Apelin is a 9 kDa protein that functions as an endog-
enous ligand of the orphan G protein-coupled apelin receptor 
(APLNR) and is expressed in various tissues throughout the 
body [9, 10]. The serum concentration of apelin is approxi-
mately 1.31 ± 0.12  ng/ml [11]. Our laboratory recently 
reported that the basal apelin concentration in epithelial 
and granulosa cancer cells is approximately 0.4 and 0.6 ng/
ml, respectively [7]. Apelin is a multifunctional regula-
tory peptide involved in a broad range of physiological and 
pathological functions, including energy metabolism, food 
intake, hormone release, immune responses, angiogenesis, 
and carcinogenesis [12–15]. Binding of apelin to its receptor 
activates the ERK and PI3K pathways in lymphatic endothe-
lial cells, which increases their proliferation, migration, and 
survival [16, 17]. Recent studies demonstrated that apelin 
expression is increased in various cancers, including those 
of the colon [18], lung [13, 19], and oral cavity [20].
Chemerin, also known as tazarotene-induced gene 2 
(TIG-2) and retinoic acid receptor responder 2 (RARRES2), 
is an 18  kDa inactive pro-protein that is activated via 
removal of a C-terminal hexapeptide by extracellular ser-
ine proteases and binds to G protein-coupled chemokine-
like receptor 1 (CMKLR1) [21]. The serum concentration 
of chemerin is positively correlated with body fat, visceral 
adipose tissue, and serum triglycerides [22, 23], and report-
edly ranges from 7 to 270 ng/ml [24–27]. Our previous study 
indicated that the basal chemerin concentration in epithelial 
and granulosa cancer cells is approximately 11.1 and 3.6 ng/
ml, respectively [8]. Chemerin derived from adipose tissue is 
involved in adipogenesis, differentiation, and chemotaxis in 
the innate immune system [28]. In primary human granulosa 
cells, chemerin decreases insulin-like growth factor-1 (IGF-
1)-induced thymidine incorporation as well as progesterone 
and estradiol production via decreased phosphorylation of 
the β subunit of IGF-1 receptor (IGF1R) and the MAPK/
ERK1/2 signaling pathways [29].
Ovarian cancer is the seventh most commonly diag-
nosed cancer in women worldwide and is the leading cause 
of death from gynecological malignancies [30]. Due to its 
non-specific symptoms, most cases of ovarian cancer present 
at a late stage. Unfortunately, the 5 year relative survival 
rate is only 29% [31]. Nearly all benign and malignant ovar-
ian tumors originate from one of three cell types: epithe-
lial, stromal, and germ cells. Epithelial ovarian cancer is 
the most common pathologic subtype and accounts for 90% 
of malignant ovarian tumors, while 5–6% of such tumors 
are sex cord-stromal tumors (e.g., granulosa cell tumors and 
thecomas) and 2–3% are germ cell tumors (e.g., teratomas 
and dysgerminomas) [32].
Estrogens play a key role in ovarian cancer progression. 
17β-estradiol (E2), which is the most potent naturally occur-
ring estrogen, is implicated in the etiology and pathogenesis 
of ovarian cancer [33]. Estrogens promote tumor progression 
by binding to nuclear estrogen receptor alpha (ERα), estro-
gen receptor beta (ERβ), or G protein-coupled receptor 30 
(GPR30), a novel membrane receptor that promotes specific 
binding of endogenous estrogens. Proper functioning of the 
female reproductive system is dependent on several impor-
tant factors that constantly interact with each other. IGF-1 
and IGF1R are key intraovarian regulators of oocyte devel-
opment, including folliculogenesis, atresia, steroidogenesis, 
and oocyte maturation. IGF-1 stimulates ovarian cancer cell 
proliferation, invasion, and angiogenesis [34–36]. Addi-
tionally, overexpression of IGF-1 and IGF1R is associated 
with ovarian cancer progression and correlates with a poor 
prognosis. Crosstalk between IGF-1 signaling and estrogen 
signaling may be important for functional regulation in ovar-
ian cancer cells. Additionally, crosstalk between the IGF-1 
pathway and ERα is well studied in breast cancer cells [37]. 
E2, IGF-1, apelin, and chemerin activate the same signal-
ing pathways; therefore, we hypothesized that crosstalk may 
occur between these hormones in ovarian cancer cells.
Thus, this study investigated whether apelin and chemerin 
at concentrations measured in human ovaries and serum 
interact with E2 and IGF-1 to regulate proliferation and 
apoptosis of epithelial (OVCAR-3) and granulosa (COV434) 
ovarian cancer cell lines. We also examined which signaling 
pathways are involved in these actions.
Materials and methods
Cell culture and chemicals
The OVCAR-3 human ovarian serous carcinoma cell line 
was obtained from the American Type Culture Collection 
(Manassas, VA, USA). The COV434 granulosa ovarian 
tumor cell line was obtained from the European Collection 
of Authenticated Cell Cultures (Sigma-Aldrich, St. Louis, 
MO, USA). OVCAR-3 cells were cultured in RPMI 1640 
medium (Thermo Fisher Scientific Inc., Carlsbad, CA, USA) 
supplemented with 15% heat-inactivated fetal bovine serum 
(Biowest, Nuaillé, France). COV434 cells were cultured in 
DMEM (Sigma-Aldrich) supplemented with 2 mM l-glu-
tamine (Thermo Fisher Scientific) and 10% fetal bovine 
serum. All cultures were maintained at 37 °C in a humidi-
fied atmosphere containing 5%  CO2.
Apelin-13 (Cat. No. A6469) and E2 (Cat. No. E2785) 
were obtained from Sigma-Aldrich. Chemerin (16 kDa; 
Cat. No. 2324-CM-025) was purchased from R&D Systems 
(Minneapolis, MN, USA). IGF-1 (Cat. No. PHG0071) was 
obtained from Gibco (Thermo Fisher Scientific). E2 was 
dissolved in absolute ethanol, while IGF-1 was dissolved 
in Cell Culture Water containing 0.1% bovine serum albu-
min (Thermo Fisher Scientific). 1,3-Bis(4-hydroxyphenyl)-
4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole 
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dihydrochloride (MPP dihydrochloride), 4-[2-phenyl-
5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]
phenol (PHTPP), 2-(2-amino-3-methoxyphenyl)-4H-1-ben-
zopyran-4-one (PD98059), (3aS*,4R*,9bR*)-4-(6-bromo-
1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta[c]quinoline 
(G15), and 5-[(4-nitrobenzoyl)oxy]-2-[(2-pyrimidinylthio)
methyl]-4H-pyran-4-one (ML221) were purchased from 
Tocris Bioscience (Bristol, UK). LY294002 was obtained 
from Cell Signaling Technology (Danvers, MA, USA). 
MPP, PHTPP, PD98059, G15, ML221, and LY294002 were 
dissolved in DMSO. The final concentration of ethanol or 
DMSO in the cell culture medium was lower than 0.1% 
(v/v), which did not affect cell viability. Control cells were 
treated with the appropriate solvent alone at a final concen-
tration lower than 0.1%.
Cell treatment
OVCAR-3 and COV434 cells were seeded into 96-well 
plates at 70% confluency in standard medium and cultured 
for 24 h. To investigate the effects of apelin (0.4, 0.6, and 
2 ng/ml) and chemerin (3, 10, and 50 ng/ml) together with 
E2 (1 nM) or IGF-1 (100 ng/ml) on cell proliferation, cells 
was treated with the test compounds for 48 or 72 h. To inves-
tigate the involvement of signal transduction pathways in 
the effects of the test compounds on cell proliferation, cells 
were pretreated with the MAPK inhibitor PD098059 (5 μM) 
or the PI3K inhibitor LY294002 (0.1 μM) for 2 h. The con-
centrations of inhibitors were chosen based on preliminary 
dose-dependent experiments. To investigate the involvement 
of specific receptors in the effects of the test compounds, 
cells were pretreated with selective antagonists of ERα 
(MPP; 10 nM), ERβ (PHTPP; 100 nM), GPR30 (G15; 1 
μM), and IGF1R (PPP; 100 nM) for 2 h and then exposed to 
the test compounds for 48 or 72 h.
Real‑time PCR analysis
Total RNA was isolated and cDNA was synthesized at 
baseline and after treatment with apelin and chemerin alone 
for 24 h using a TaqMan Gene Expression Cells-to-CT Kit 
(Applied Biosystems, Foster City, CA, USA) according 
to the manufacturer’s instructions. The lysis solution con-
tained DNase I to remove genomic DNA contamination. The 
resulting pre-amplified cDNA preparations were analyzed by 
real-time PCR using a StepOnePlus Real-Time PCR System 
(Applied Biosystems) and TaqMan Gene Expression Assays 
in combination with TaqMan Gene Expression Master Mix 
containing ROX Reference Dye (Applied Biosystems). 
The thermal cycling conditions were as follows: 50 °C for 
2 min, 95 °C for 10 min, and then 40 cycles of 95 °C for 
15 s and 60 °C for 60 s. The following TaqMan gene expres-
sion assays were used: ERα (ESR1; Hs00174860_m1), ERβ 
(ESR2; Hs01100353_ml), GPR30 (GPER; Hs01922715_sl), 
and IGF1R (IGF1R; Hs00609566_ml). Expression lev-
els were normalized against that of GADPH (Assay No. 
4310884E). Relative expression was quantified using the 
 2−ΔΔCt method [38].
Cell proliferation assay
Cell proliferation was assessed using the CellTiter-Glo 
Luminescent Cell Viability Assay (Promega, Charbonnieres-
les-Bains, France), which determines the number of viable 
cells based on quantitation of ATP, an indicator of meta-
bolically active cells. Luminescence was measured using a 
SpectraMax L luminometer (Molecular Devices, San Jose, 
CA, USA) according to the manufacturer’s instructions.
Caspase‑3 activity assay
The culture medium was replaced by serum-free medium 
24 h prior to the experiment. Cells were treated with vehi-
cle, apelin (0.4, 0.6, and 2 ng/ml), or chemerin (3, 10, and 
50 ng/ml) for 24 h. The medium was then removed, and the 
plates were stored at −70 °C. Cells were lysed in caspase 
assay buffer (50 mM HEPES, pH 7.4, 100 mM NaCl, 0.1% 
CHAPS, 1 mM EDTA, 10% glycerol, and 10 mM DTT). The 
protein concentrations of the lysates were determined using 
the reactive compound fluorescamine (MP Biomedicals, 
Illkirch Cedex, France). An equal amount of the cytosolic 
extract (100 μg of protein) from each sample was analyzed. 
The assay was performed by adding 100 μM Ac-DEVDAMC 
(Sigma-Aldrich) and incubating the plates at 37 °C. The 
amount of fluorescent product was monitored continuously 
for 120 min using a spectrofluorometer (FLx800; BioTek 
Instruments, Winooski, VT, USA) at an excitation wave-
length of 355 nm and an emission wavelength of 460 nm. 
Data were analyzed using KC JUNIOR software and nor-
malized against the level of fluorescence in vehicle-treated 
cells.
Western blot analysis
After treating cells with test compounds for 24 or 48 h, 
cells were lysed in lysis buffer. Proteins were separated 
in 4–20% Mini-Protean TGX System Precast Protein Gels 
(Bio-Rad, Hercules, CA, USA) and transferred to Trans-
Blot Turbo Mini PVDF Transfer Packs (Bio-Rad) using a 
Trans- Blot Turbo Transfer System apparatus (Bio-Rad). 
The blots were blocked for 1 h in 0.02 M Tris-buffered 
saline containing 5% bovine serum albumin and 0.1% 
Tween 20 and then incubated overnight at 4  °C with 
antibodies specific for caspase-3 and cleaved caspase-3 
(#9662, Cell Signaling Technology), PARP (#9542, 
Cell Signaling Technology), ERα (sc-8002, Santa Cruz 
6328 Molecular Biology Reports (2019) 46:6325–6338
1 3
Biotechnology), ERβ (sc-8974, Santa Cruz Biotechnol-
ogy), and GPR30 (ab3974, Abcam). The membranes were 
then washed three times in TBST (Tris-buffered saline, 
0.1% Tween 20) and incubated for 1 h at room tempera-
ture with horseradish peroxidase (HRP)-conjugated anti-
rabbit (#7074) secondary antibodies (Cell Signaling Tech-
nology). β-Actin (Cat. No. A5316, Sigma-Aldrich) was 
used as a loading control. Immunopositive bands were 
visualized using WesternBright Quantum HRP substrate 
(Cat. No. K- 12043 D20, Advansta Inc., Menlo Park, CA, 
USA). Quantification of protein bands was performed by 
densitometry using VisionWorks LS Acquisition and 
Analysis software (UVP, LLC, Upland, CA, USA).
Statistical analysis
Data are presented as the mean ± SD of three independent 
experiments performed in triplicate. Statistical analysis 
was performed using a one-way ANOVA followed by 
Tukey’s test (GraphPad Prism Software, La Jolla, CA, 
USA). The level of significance was set at P < 0.05. Pro-
liferation and apoptosis were compared between two 
groups using the non-parametric Mann–Whitney U test. 
P <0.05 was considered statistically significant.
Results
Our recent studies showed that OVCAR-3 cells secrete 
apelin and chemerin at concentrations of 0.4 and 10 ng/
ml, respectively, while COV434 cells secrete apelin and 
chemerin at concentrations of 0.6 and 3 ng/ml, respec-
tively [7, 8]. Therefore, apelin and chemerin were used at 
these concentrations in the current study. As mentioned 
in section “Introduction”, adipokines are expressed in 
various tissues in the human body and function in par-
acrine and autocrine manners. Therefore, we considered 
the serum concentrations. Consequently, we also used 
apelin and chemerin at concentrations of 2 and 50 ng/ml, 
respectively, based on their average serum concentrations.
Effects of apelin and chemerin on the proliferation/
apoptosis (P/A) ratio
The pro-carcinogenic effects of adipokines are not only due 
to increased activity of signaling pathways involved in pro-
liferation, but probably also to downregulation of apoptosis. 
Therefore, we assessed the effects of apelin and chemerin 
on the P/A ratio of OVCAR-3 and COV434 cells. Apoptosis 
was evaluated by measuring caspase-3 activity after treat-
ment with apelin or chemerin for 24 h. Apelin (0.4 or 0.6 
and 2 ng/ml) and chemerin (3 or 10 and 50 ng/ml) did not 
affect caspase-3 activity in either cell line. Proliferation was 
evaluated by determining the number of viable cells based 
on quantitation of ATP, an indicator of metabolically active 
cells, and then the P/A ratio was calculated. Apelin signifi-
cantly increased the P/A ratio of OVCAR-3 cells (P/A = 1.16, 
P = 0.0006 for 0.4 ng/ml; and P/A = 1.21, P < 0.0001 for 
2 ng/ml), but did not significantly affect that of COV434 
cells. Caspase-3 as a crucial executioner of apoptosis, is also 
responsible for the proteolytic cleavage of many key pro-
teins. Cleavage and therefore activation of caspase-3 leads to 
cleavage of nuclear enzyme Poly (ADP-ribose) polymerase 
(PARP) that is known to be a terminal step of apoptosis. 
Thus, we evaluated the effect of apelin on caspase-3, cleaved 
caspase-3 as well as cleaved PARP protein expression in 
OVCAR-3 cells. Apelin at all tested concentrations had 
no effect on OVCAR-3 caspase-3 and cleaved PARP pro-
tein expression (Fig. 1a, b). Chemerin did not significantly 
affect the P/A ratio of either cell line (Table 1; P > 0.05). 
These results indicate that apelin increases proliferation of 
OVCAR-3 cells, but does not affect apoptosis.
Effects of apelin and chemerin in combination 
with E2 on cell proliferation
Apelin and E2 were previously reported to affect prolif-
eration of epithelial ovarian cancer cells. This prompted 
us to investigate the effects of co-treatment with apelin 
and E2 on cell proliferation. Consistent with the previ-
ous results, treatment with apelin at concentrations meas-
ured in epithelial ovarian cancer cells (0.4 ng/ml) and 
serum (2 ng/ml) increased proliferation of OVCAR-3 cells 
(114 ± 4% and 115 ± 4% relative to that of control cells, 
respectively) (Fig. 2a; P < 0.001). Similarly, E2 (1 nM) 
increased proliferation of OVCAR-3 cells (112 ± 4%) 
(Fig.  2a; P < 0.05). However, apelin abrogated the 
E2-induced increase in OVCAR-3 cell proliferation; co-
treatment with apelin and E2 decreased proliferation to 
the control level (99 ± 3% and 99 ± 1% upon co-treatment 
with E2 and 0.4 or 2 ng/ml apelin, respectively) (Fig. 2a). 
Furthermore, apelin and E2 did not affect proliferation of 
COV434 cells (Fig. 2b).
Fig. 1  Effect of apelin (0.4 and 2 ng/ml) on a caspase-3 and b cleaved 
PARP protein expression in OVCAR-3 cells after 48 h of treatment. 
C control
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Next, we examined the effect of co-treatment with 
chemerin and E2 on proliferation of OVCAR-3 and 
COV434 cells. According to our previous study, chemerin 
did not affect proliferation of either cell line. Consistently, 
Table 1  Effects of (a) apelin (0.4 or 0.6 and 2 ng/ml) and (b) chemerin (3 or 10 and 50 ng/ml) on proliferation and apoptosis of OVCAR-3 and 
COV434 cells
Apoptosis and proliferation were assessed by measuring caspase-3 activity and quantifying ATP, respectively, as described in section “Materials 
and methods”. Results are presented as the mean ± SD
***P < 0.05 (compared with control untreated cells)
(a) OVCAR-3 COV434
Apelin
0.4 ng/ml 2 ng/ml 0.6 ng/ml 2 ng/ml
Proliferation (%) 114.1 ± 4.3 115.5 ± 4.3 97.8 ± 8.9 103.1 ± 9.4
Apoptosis (%) 97.1 ± 8.2 95.1 ± 11.5 102.3 ± 10.2 97.1 ± 9.7
Proliferation/apoptosis ratio 1.16*** 1.21*** 0.96 1.06
(b) OVCAR-3 COV434
Chemerin
10 ng/ml 50 ng/ml 3 ng/ml 50 ng/ml
Proliferation (%) 109.2 ± 8.5 109.2 ± 10.1 102.2 ± 6.5 106.5 ± 6.4
Apoptosis (%) 93.7 ± 16.1 97.0 ± 37.6 102.7 ± 17.4 107.5 ± 19.4
Proliferation/apoptosis ratio 1.17 1.13 0.96 0.99
Fig. 2  Effect of apelin (0.4 or 0.6 and 2 ng/ml) in combination with 
E2 (1  nM) on proliferation of a OVCAR-3 and b COV434 cells. 
Effect of chemerin (3 or 10 and 50  ng/ml) in combination with E2 
(1 nM) on proliferation of c OVCAR-3 and d COV434 cells. C con-
trol. *P < 0.05, ***P < 0.001 (compared with control untreated cells)
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chemerin (10 and 50 ng/ml) did not affect proliferation 
of OVCAR-3 cells. Moreover, chemerin did not influence 
the stimulatory effect of E2 (1 nM) on proliferation of 
OVCAR-3 cells (Fig. 2c). Treatment with chemerin alone 
(3 and 50 ng/ml) or in combination with E2 (1 nM) did 
not affect proliferation of COV434 cells (Fig. 2d).
Based on these results, subsequent experiments were 
conducted to investigate the antagonistic effect of apelin 
on E2-induced proliferation of OVCAR-3 cells.
Mechanism by which apelin abrogates E2‑induced 
proliferation of OVCAR‑3 cells
Role of the ERK1/2 and PI3K pathways in the effects 
of apelin on E2‑induced proliferation of OVCAR‑3 cells
We investigated whether the ERK1/2 and PI3K path-
ways are involved in the antagonistic effect of apelin on 
E2-induced proliferation of OVCAR-3 cells. Pretreatment 
with the ERK1/2 inhibitor PD098059 (5 μM) for 2 h prior 
to exposure to the test compounds for 48 h abrogated the 
stimulatory effects of apelin (2 ng/ml) and E2 (1 nM) 
alone on cell proliferation. Co-treatment with apelin and 
E2 following pretreatment with PD098059 did not affect 
cell proliferation (Fig. 3a). These data indicate that the 
ERK1/2 pathway is not involved in the antagonistic effect 
of apelin on E2-induced proliferation of OVCAR-3 cells.
We next investigated whether blockade of the PI3K 
pathway abrogates the antagonistic effect of apelin on 
E2-induced proliferation of OVCAR-3 cells. Pretreatment 
with the PI3K inhibitor LY294002 (0.1 μM) abrogated 
the stimulatory effects of E2 and apelin alone on cell 
proliferation. Co-treatment with apelin and E2 following 
pretreatment with LY294002 did not affect cell prolif-
eration (Fig. 3b). These data suggest that the PI3K path-
way is not involved in the antagonistic effect of apelin on 
E2-induced proliferation of OVCAR-3 cells.
Role of APLNR, ERα, ERβ, and GPR30 in the effects of apelin 
on E2‑induced proliferation of OVCAR‑3 cells
To elucidate how apelin abrogates E2-induced prolifera-
tion of OVCAR-3 cells, we assessed its effect on classical 
(ERα and ERβ) and non-classical (GPR30) estrogen recep-
tors. Apelin (0.4 and 2 ng/ml) did not affect expression 
of ERα, ERβ, and GPR30 in OVCAR-3 cells (Fig. 4a–c). 
After treating OVCAR-3 cells with apelin the ERα, ERβ, 
and GPR30 protein levels were examined by Western blot 
analysis, and the results mirrored those from real-time PCR 
analyses (Fig. 4d–f). This result suggests that apelin does 
not abrogate E2-induced proliferation of OVCAR-3 cells by 
changing estrogen receptor expression.
To investigate the mechanism by which apelin (2 ng/ml) 
abrogates the stimulatory effect of E2 (1 nM) on prolifera-
tion of OVCAR-3 cells, we pretreated cells with inhibitors 
of APLNR, ERα, ERβ, and GPR30 (ML221: 10 μM, MPP: 
10 nM, PHTPP: 10 nM, and G15: 1 μM, respectively) for 
2 h and then exposed them to apelin and E2 for 48 h. As 
expected, ML221 abolished the stimulatory effect of apelin 
on cell proliferation (121 ± 10% vs. 102 ± 11%) (Fig. 4g). 
Cell proliferation upon co-treatment with apelin and E2 
was similar regardless of whether cells were pretreated 
with or without ML221 (104 ± 10% vs. 103 ± 8%) (Fig. 4g). 
Similarly, MPP abolished the stimulatory effect of apelin 
on cell proliferation (102 ± 7%). Cell proliferation upon co-
treatment with apelin and E2 following pretreatment with 
MPP was similar to that of control cells (96 ± 6%) (Fig. 4h). 
However, apelin still increased cell proliferation following 
pretreatment with PHTPP or G15 (119 ± 7% and 117 ± 6%, 
respectively), and this effect was blocked in the presence 
of E2 (Fig. 4i, j). These results demonstrate that ERβ and 
GPR30 are not involved in the effects of apelin and E2 on 
cell proliferation and indicate that crosstalk occurs between 
APLNR and ERα.
Fig. 3  Influence of a ERK1/2 and b PI3K inhibition on the effects of 
apelin (2 ng/ml) and E2 on OVCAR-3 cell proliferation. Cells were 
pretreated with the ERK1/2 inhibitor PD098059 (5 μM) or the PI3K 
inhibitor LY294002 (0.1  μM) for 2  h and then exposed to the indi-
cated test compounds for 48 h (in the presence of inhibitors). C con-
trol (not exposed to a test compound). *P < 0.05, ***P < 0.001 (com-
pared with control untreated cells)
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Fig. 4  Effects of treatment with apelin (0.4 and 2 ng/ml) on mRNA 
(a–c) and protein (d–f) expression of ERα, ERβ, and GPR30 in 
OVCAR-3 cells. RQ, relative quantity. The expression level in control 
cells was arbitrarily set to 1. Role of g APLNR, h ERα, i ERβ, and j 
GPR30 in the effects of apelin (2 ng/ml) and E2 (1 nM) on OVCAR-3 
cell proliferation. Cells were pretreated with APLNR, ERα, ERβ, and 
GPR30 inhibitors (ML221: 10 μM, MPP: 10  nM, PHTPP: 10  nM, 
and G15: 1 μM, respectively) for 2 h and then exposed to apelin and 
E2. ***P < 0.001 (compared with control untreated cells)
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Effects of apelin and chemerin in combination 
with IGF‑1 on cell proliferation
IGF-1 stimulates proliferation of epithelial and granulosa 
ovarian cancer cell lines. Therefore, we assessed the effects 
of co-treatment with apelin or chemerin and IGF-1 on cell 
proliferation. Treatment with IGF-1 (100 ng/ml) alone for 
48 h significantly increased proliferation of OVCAR-3 and 
COV434 cells (118 ± 7% and 123 ± 12%, respectively) 
(Fig. 5; P < 0.001). Apelin (0.4 and 2 ng/ml) did not affect 
IGF-1-induced proliferation of OVCAR-3 cells. However, 
proliferation of COV434 cells was decreased to the control 
level upon co-treatment with apelin (0.6 and 2 ng/ml) and 
IGF-1 (108 ± 10% and 111 ± 10%, respectively) (Fig. 5b). 
This result indicates that apelin antagonizes the stimulatory 
effect of IGF-1 on proliferation of COV434 cells.
Parallel experiments were conducted using chemerin and 
IGF-1. Chemerin did not affect cell proliferation and did not 
abrogate the stimulatory effects of IGF-1 on proliferation of 
either cell line (Fig. 5c, d).
Mechanism by which apelin abrogates 
IGF‑1‑induced proliferation of COV434 cells
Role of the ERK1/2 and PI3K pathways in the effects 
of apelin on IGF‑1‑induced proliferation of COV434 cells
To investigate which signaling pathways are involved in the 
effects of apelin on IGF-1-induced proliferation of COV434 
cells, cells was pretreated with the ERK1/2 inhibitor 
PD098059 (5 μM) or the PI3K inhibitor LY294002 (0.1 μM) 
for 2 h and then exposed to the test compounds for 48 h. Block-
ade of the ERK1/2 and PI3K signaling pathways abrogated the 
stimulatory effect of IGF-1 (100 ng/ml) alone on cell prolif-
eration, but did not influence the antagonistic effect of apelin 
(2 ng/ml) on IGF-1-induced cell proliferation. These data indi-
cate that the ERK1/2 and PI3K pathways are not involved in 
the antagonistic effect of apelin on IGF-1-induced proliferation 
of COV434 cells (Fig. 6).
Fig. 5  Effect of apelin (0.4 or 0.6 and 2 ng/ml) in combination with 
IGF-1 (100  ng/ml) on proliferation of a OVCAR-3 and b COV434 
cells. Effect of chemerin (3 or 10 and 50 ng/ml) in combination with 
IGF-1 (100  ng/ml) on proliferation of c OVCAR-3 and d COV434 
cells. C control. **P < 0.01, ***P < 0.001 (compared with control 
untreated cells)
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Role of the APLNR signaling pathway in the effects of apelin 
on IGF‑1‑induced proliferation of COV434 cells
To elucidate how apelin inhibits IGF-1-induced proliferation 
of COV434 cells, we assessed its effect on IGF1R expres-
sion. Apelin (0.6 and 2 ng/ml) did not affect mRNA expres-
sion of IGF1R in COV434 cells (Fig. 7a). This result suggests 
that apelin does not abrogate IGF-1-induced proliferation of 
COV434 cells by altering IGF1R expression. The role of the 
APLNR pathway was further evaluated. Pretreatment with the 
APLNR inhibitor ML221 (10 μM) abrogated the stimulatory 
effect of IGF-1 (100 ng/ml) on proliferation of COV434 cells 
(Fig. 7b). We conclude that apelin abrogates the stimulatory 
effect of IGF-1 on proliferation of COV434 cells via crosstalk 
between APLNR and IGF1R.
Discussion
Adipokines are present in the female reproductive system. In 
fact, adipokines and their receptors are expressed in human 
reproductive tissue and may thus act in an autocrine manner 
[39]. Our previous studies showed that apelin and chemerin 
are expressed in human ovarian cancer cell lines and that 
their expression ratio differs according to where the cells 
are derived from (epithelial vs. granulosa) [7, 8]. Thus, the 
present study investigated if apelin and chemerin influence 
apoptosis and proliferation of ovarian cancer cells by inter-
acting with two major regulators of ovarian functions (E2 
and IGF-1).
We investigated whether treatment with apelin and 
chemerin at concentrations measured in ovarian cancer cells 
and serum influences apoptosis of OVCAR-3 and COV434 
cells. Apelin and chemerin did not significantly affect cas-
pase-3 activity, indicating that they do not activate apoptotic 
cell death, in which caspase-3 is the executioner enzyme. 
Apelin only affected proliferation of epithelial ovarian can-
cer cells, consistent with our previous study [7]. Calculation 
of the P/A ratio revealed that apelin increased proliferation 
of OVCAR-3 cells, but did not inhibit apoptosis. However, 
inhibition of apoptosis is a hallmark of cancer and apoptosis 
is decreased in cancer cells. By contrast, previous studies 
suggest that apelin regulates apoptosis of various non-cancer 
cell types via different mechanisms. Apelin protects against 
apoptosis in cardiac tissues by regulating FoxO1 in mice 
[40] and by upregulating Bcl-2 and downregulating Bax 
together with cleaved caspase-3 in rats [41]. In addition, 
apelin alleviates oxidative stress and mitochondria-medi-
ated apoptosis in mice [42]. Apelin induces expression of 
the antiapoptotic protein B cell lymphoma 2 and decreases 
production of the proapoptotic protein Bax in osteoblasts 
[43]. Moreover, apelin elicits a protective effect in the brain 
[44, 45] by inhibiting activation of the JNK and P38MAPK 
Fig. 6  Influence of a ERK1/2 and b PI3K inhibition on the effects of 
apelin (2 ng/ml) and IGF-1 on proliferation of COV434 cells. Cells 
were pretreated with the ERK1/2 inhibitor PD098059 (5 μM) or the 
PI3K inhibitor LY294002 (0.1 μM) for 2 h and then exposed to the 
indicated test compounds for 48 h (in the presence of the inhibitors). 
C control (not exposed to a test compound). ***P < 0.001 (compared 
with control untreated cells)
Fig. 7  a Effects of treatment with apelin (0.6 and 2 ng/ml) for 24 h on 
mRNA expression of IGF1R in COV434 cells. RQ relative quantity. 
The expression level in control cells was arbitrarily set to 1. b The 
role of APLNR signaling in the effects of apelin (2 ng/ml) and IGF-1 
(100 ng/ml). Cells were pretreated with the APLNR inhibitor ML221 
(10 μM) for 2 h and then exposed to apelin and IGF-1. ***P < 0.001 
(compared with control untreated cells)
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signaling pathway in damaged neurons [46]. Apelin also 
inhibits apoptosis of endothelial cells [47], retinal Muller 
cells [48], and smooth muscle cells [49]. However, Roche 
et al. [50] reported that apelin does not affect apoptosis of 
bovine granulosa cells. There is a lack of data concerning the 
influence of chemerin on apoptosis. Rodríguez-Penas et al. 
[51] reported that chemerin induces apoptosis, reduces AKT 
phosphorylation, and increases caspase-9 cleavage in murine 
cardiomyocytes, suggesting that chemerin plays a role in the 
physiopathology of cardiac diseases.
Estrogen levels in ovarian tissue are at least 100-fold 
higher than circulating levels, indicating that estrogens are 
implicated in progression of ovarian cancer [52]. Therefore, 
we next focused on the interaction of apelin and chemerin 
with E2. Treatment with apelin at concentrations measured 
in ovarian cancer cells and serum abrogated the stimula-
tory effect of E2 on proliferation of OVCAR-3 cells. Simi-
larly, our previous study demonstrated that treatment with 
leptin or E2 alone stimulates migration of OVCAR-3 cells, 
while co-treatment does not [53]. Furthermore, adiponectin 
abrogates the stimulatory effect of E2 on proliferation of 
OVCAR-3 cells [54]. Upon co-treatment of COV434 cells 
with apelin and E2, the level of proliferation was similar to 
that of control cells. E2 affects proliferation of non-cancer 
granulosa cells [55], but not of granulosa tumor cells [56]. 
We next investigated which signaling pathways are involved 
in the antagonistic effect of apelin on E2-induced prolifera-
tion of OVCAR-3 cells. PD098059 and LY294002 were used 
to block the ERK1/2 and PI3K pathways, respectively. Cell 
proliferation induced by apelin or E2 alone was blocked by 
pretreatment with these inhibitors. This result is consistent 
with previous reports that ERK1/2 and PI3K function in 
E2-stimulated cancer progression. Additionally, we previ-
ously reported that E2 stimulates migration of OVCAR-3 
cells via the ERK1/2 and PI3K pathways [57]. Apelin acti-
vates PI3K/Akt in human granulosa cells [58]. Activation of 
the ERK1/2 signaling pathway by apelin induces prolifera-
tion and invasion of MCF-7 cells [59]. Binding of apelin to 
its receptor activates the ERK and PI3K pathways in lym-
phatic endothelial cells, which increases their proliferation, 
migration, and survival [16, 17]. However, the ERK1/2 and 
PI3K inhibitors did not affect the antagonistic effect of ape-
lin on E2-induced proliferation of OVCAR-3 cells. These 
data indicate that apelin and E2 activate the same signaling 
pathways, but the ERK1/2 and PI3K pathways do not medi-
ate the antagonistic effect of apelin on E2-induced prolifera-
tion of OVCAR-3 cells.
We also examined if apelin affects mRNA expression of 
classical (ERα and ERβ) and non-classical (GPR30) estrogen 
receptors. Apelin (0.4 and 2 ng/ml) did not affect expression 
of these receptors in OVCAR-3 cells. Our previous study 
demonstrated that E2 (1 and 10 nM) does not affect expres-
sion of apelin or its receptor in OVCAR-3 cells [7]. These 
results indicate that apelin does not abrogate E2-stimulated 
cell proliferation by altering estrogen receptor expression. 
Next, we investigated whether crosstalk occurs between 
APLNR and estrogen receptors. Pharmacological inhibi-
tion of APLNR and ERα abrogated the effects of E2 and 
apelin on proliferation of OVCAR-3 cells, while pharma-
cological inhibition of ERβ and GPR30 did not. A possible 
interaction between adipokine and estrogen receptors has 
been reported. Fusco et al. [60] demonstrated a significant 
correlation between expression of the leptin receptor and 
ERα. Additionally, leptin indirectly promotes proliferation 
and migration of breast cancer cells via estrogen signaling 
pathways, indicating that hormone-mediated pro-carcino-
genic crosstalk occurs [61]. Our results demonstrate for the 
first time that crosstalk occurs between APLNR and ERα in 
epithelial ovarian cancer cells.
Role of IGF-1 in regulation of ovarian functions and 
steroidogenesis is already well known [62, 63]. Interactions 
between IGF-1 and other hormones produced by ovarian 
cells are important for proper functioning of human ovaries. 
The present study showed that apelin in combination with 
IGF-1 stimulated proliferation of OVCAR-3 cells, and this 
effect was not greater than that of each compound alone. 
Similarly, Rak et al. [64] reported that IGF-1 significantly 
increases cell proliferation in porcine ovarian follicles, 
although apelin (2 ng/ml) does not enhance the effects of 
IGF-1. However, apelin abrogated IGF-1-stimulated pro-
liferation of COV434 cells. It is worth noting that apelin 
alone did not affect proliferation of COV434 cells, simi-
lar to chemerin. Consistently, we previously reported that 
adiponectin abrogates the stimulatory effect of IGF-1 on 
proliferation of OVCAR-3 cells [54]. Moreover, we demon-
strated that these effects were not mediated via the ERK1/2 
and PI3K pathways using chemical inhibitors. These signal-
ing pathways were examined because binding of IGF-1 to 
its tyrosine kinase receptor IGF1R activates PI3K/Akt and 
MAPK/ERK, leading to changes in cell proliferation, differ-
entiation, and apoptosis [65, 66]. Moreover, apelin increases 
IGF-1-induced phosphorylation of PI3K/Akt [58] and reg-
ulates steroidogenesis in granulosa cells [67, 68]. Roche 
et al. [58] reported that the PI3K/Akt signaling pathway is 
involved in the effects of apelin on IGF-1-induced steroido-
genesis in granulosa cells using pharmacological inhibitors. 
However, the current study demonstrated that the ERK1/2 
and PI3K pathways do not mediate the antagonistic effect 
of apelin on IGF-1-induced proliferation of COV434 cells. 
Next, we investigated whether apelin affects proliferation of 
COV434 cells by altering IGF1R expression or whether this 
effect is mediated by interactions between receptors. Treat-
ment with apelin at concentrations measured in granulosa 
cells and serum did not affect mRNA expression of IGF1R. 
However, pretreatment with the APLNR antagonist ML221 
abrogated IGF-1-stimulated proliferation of COV434 cells, 
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indicating that inhibition of APLNR causes IGF1R dys-
function. Crosstalk between adiponectin, a well-known 
adipokine, and IGF1R was previously reported; adiponec-
tin increases tyrosine phosphorylation of the β subunit of 
IGF1R and downstream MAPK activation in rat granulosa 
cells [1]. Mauro et al. [69] reported that crosstalk between 
adiponectin/AdipoR1 and IGF1R rapidly increases phos-
phorylation of IGF1R in ERα-positive breast cancer cells. 
Saxena et al. [70] demonstrated that bidirectional crosstalk 
between leptin and IGF-1 signaling transactivates vascular 
endothelial growth factor receptor-1 and promotes metas-
tasis, invasion, and migration of breast cancer cells. How-
ever, Ozbay and Nahta [71] showed that IGF-1 stimulates 
phosphorylation and activation of Ob-R while leptin does 
not induce phosphorylation of IGF1R, indicating that this 
regulation is unidirectional. To the best of our knowledge, 
there is no information regarding the relationship between 
APLNR inhibition and IGF1R dysfunction. We surmise that 
negative crosstalk occurs between these two receptors and 
that this underlies the antagonistic effect of apelin on IGF-
1-induced proliferation of COV434 cells.
In conclusion, apelin and chemerin did not affect cas-
pase-3 activation in epithelial and granulosa ovarian cancer 
cell lines. Apelin abolished the stimulatory effects of E2 
on proliferation of OVCAR-3 cells and of IGF-1 on pro-
liferation of COV434 cells. We speculate that these effects 
are mediated via crosstalk between APLNR and ERα/
IGF1R (Fig. 8).
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